Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Summary

This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.

Timeline

Start

2021-12-13

Primary completion

2026-04-10

Completion

2026-04-10

Drugs

Indications